Resultados positivos del análisis intermedio del ensayo de fase II ‘GEN-001’ más avelumab (Bavencio®)

Posted on by

SEÚL, Corea del sur, 19 de mayo de 2023 /PRNewswire/ — Genome & Company (consejero delegado: Pae, Jisoo), desarrollador líder mundial de terapias de microbiomas, anunció que este ensayo de fase II (NCT05419362) continuará sin modificaciones para pasar a la segunda etapa, según el…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.